Invasive breast cancer means cancer cells have broken through the walls of the milk ducts or lobules where they started and grown into surrounding breast tissue. This is different from non-invasive breast cancer (like ductal carcinoma in situ), where abnormal cells remain contained within the duct lining. Once cancer becomes invasive, it has the potential to spread to lymph nodes and other parts of the body. About 8 in 10 breast cancer diagnoses are invasive.
How Invasive Cancer Differs From Non-Invasive
Breast tissue contains a network of milk ducts and milk-producing glands called lobules. Both are lined with cells and surrounded by a thin layer of tissue called the basement membrane. In non-invasive breast cancer, abnormal cells multiply inside the ducts or lobules but stay behind that membrane. They haven’t gained the ability to push through into surrounding tissue.
Invasive cancer has crossed that line. The cells have broken through the basement membrane and are now growing in the fatty and connective tissue of the breast. From there, they can enter blood vessels or lymph channels and travel to distant organs. This is why the distinction matters so much: non-invasive cancer is highly treatable and stays put, while invasive cancer carries a risk of spreading that shapes every treatment decision.
The Two Main Types
Invasive Ductal Carcinoma (IDC)
IDC is by far the most common form, making up roughly 8 in 10 invasive breast cancers. It begins in the cells lining a milk duct, then breaks through the duct wall into nearby breast tissue. IDC typically forms a firm, distinct lump that shows up relatively well on mammograms, which is one reason it’s often caught earlier than other types.
Invasive Lobular Carcinoma (ILC)
ILC accounts for about 1 in 10 invasive breast cancers. It starts in the lobules, the small glands that produce milk. ILC tends to grow in a single-file pattern through tissue rather than forming a solid mass, which makes it harder to detect on both physical exams and mammograms. It’s also more likely to affect both breasts. About 1 in 5 women with ILC have cancer in both breasts at the time of diagnosis.
Molecular Subtypes and Why They Matter
After a biopsy confirms invasive breast cancer, the tumor is tested for specific proteins on its surface. These proteins determine which treatments will work and give doctors a clearer picture of how the cancer is likely to behave. Two tests matter most: whether the cancer cells have hormone receptors (for estrogen or progesterone) and whether they overproduce a protein called HER2.
Hormone receptor-positive (HR+) cancers rely on estrogen or progesterone to grow, which means therapies that block those hormones can slow or stop the cancer. HER2-positive cancers make excess amounts of a growth-promoting protein, making them more aggressive but also responsive to drugs that target HER2 specifically. The four main combinations, listed from most to least common, are: HR+/HER2-, HR-/HER2-, HR+/HER2+, and HR-/HER2+.
The subtype that tends to concern patients most is HR-/HER2-, sometimes called triple-negative breast cancer. It lacks all three targetable receptors, which means hormone therapies and HER2-targeted drugs won’t work. Treatment relies more heavily on chemotherapy, though newer options including immunotherapy have improved outcomes in recent years.
Signs and Symptoms
Invasive breast cancer doesn’t always cause symptoms, especially in its early stages. When it does, the most common warning signs include:
- A new lump in the breast or underarm area
- Thickening or swelling of part of the breast
- Skin changes like dimpling, irritation, redness, or flaky skin on the breast or nipple
- Nipple changes such as pulling inward (retraction), pain, or discharge other than breast milk
- Change in breast size or shape
- Breast pain in any area
Many of these symptoms can be caused by conditions that aren’t cancer, but any persistent change in the breast warrants evaluation. Invasive lobular carcinoma in particular may not produce an obvious lump, instead causing a subtle thickening or fullness that’s easy to dismiss.
How It’s Diagnosed
Imaging is usually the first step. Mammograms, ultrasounds, and MRIs can reveal suspicious areas, but none of them can confirm cancer on their own. A biopsy is the only sure way to diagnose breast cancer.
The most common approach is a core needle biopsy, where a hollow needle removes small cylinders of tissue from the suspicious area. This is usually done with ultrasound or mammographic guidance and is the preferred method when cancer is suspected. Fine needle aspiration, which uses a thinner needle to withdraw a smaller sample of tissue or fluid, is sometimes used for cysts or lymph nodes. In rare cases, a surgical biopsy is needed to remove part or all of a lump for testing.
If the biopsy confirms invasive cancer, nearby lymph nodes are typically checked to determine whether cancer has spread beyond the breast. This is done through a sentinel lymph node biopsy, often at the same time as the main surgery. The sentinel node is the first lymph node that drains the area around the tumor. If it’s clear, the remaining nodes are very likely clear too.
Staging: How Far It Has Spread
Staging tells you how large the tumor is, whether it has reached lymph nodes, and whether it has spread to distant organs. It uses three measurements: tumor size (T), node involvement (N), and metastasis (M).
For tumor size, the thresholds are straightforward. Tumors 20 millimeters (about ¾ inch) or smaller are classified as T1. Tumors between 20 and 50 millimeters are T2. Anything larger than 50 millimeters is T3, and tumors that have grown into the chest wall or skin are T4. Node involvement ranges from N0 (no cancer in lymph nodes) through N3 (cancer in 10 or more underarm nodes or spread above or below the collarbone). Metastasis is either M0 (no distant spread) or M1 (cancer has spread to other organs).
These measurements combine into an overall stage from I through IV. Modern staging also factors in the tumor’s molecular subtype, because a small hormone receptor-positive tumor behaves very differently from a small triple-negative one, even if they’re the same physical size.
Treatment Options
Surgery is the cornerstone of treatment for most invasive breast cancers. The two main options are lumpectomy, which removes the tumor along with a margin of healthy tissue while preserving the rest of the breast, and mastectomy, which removes the entire breast. Breast reconstruction is possible with either approach, though it’s more commonly discussed after mastectomy.
Most people with invasive cancer also receive additional therapy to reduce the chance of the cancer returning. What that looks like depends on the molecular subtype. Hormone receptor-positive cancers are typically treated with hormone-blocking pills taken for 5 to 10 years. HER2-positive cancers receive targeted therapy, often combined with chemotherapy. Triple-negative cancers are more likely to require chemotherapy, sometimes given before surgery to shrink the tumor first.
Radiation therapy is standard after lumpectomy and sometimes recommended after mastectomy, particularly when the tumor was large or lymph nodes were involved. A typical course runs five days a week for several weeks, though shorter schedules are increasingly available.
Survival Rates by Stage
The prognosis for invasive breast cancer depends heavily on how early it’s caught. The five-year relative survival rate for localized disease, meaning the cancer is still confined to the breast, is 100%. When cancer has spread to regional lymph nodes, that number drops to 87.5%. For distant-stage cancer that has metastasized to other organs, the five-year survival rate is 33.8%.
These numbers reflect outcomes across all molecular subtypes and treatment approaches. Individual prognosis varies based on the cancer’s subtype, grade (how abnormal the cells look under a microscope), and how well it responds to treatment. Hormone receptor-positive cancers, which are the most common subtype, generally carry a more favorable prognosis than triple-negative cancers of the same stage.
Where Invasive Breast Cancer Can Spread
When invasive breast cancer metastasizes, it most commonly travels to the bones, lungs, liver, and brain. The cancer first spreads into surrounding breast tissue and nearby lymph nodes, particularly those in the armpit. From there, cells can enter the bloodstream and establish new tumors in distant organs. Invasive lobular carcinoma has a somewhat different pattern, with a higher tendency to spread to the lining of the abdomen and the ovaries compared to ductal carcinoma.
Metastatic breast cancer (stage IV) is treatable but not curable with current therapies. Treatment focuses on controlling the disease, managing symptoms, and maintaining quality of life for as long as possible. Many people with metastatic breast cancer live for years with ongoing treatment, particularly those with hormone receptor-positive disease.